Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
In Memoriam Professor Dr. Hendrik Lacroix.

Acta chirurgica Belgica

Nevelsteen A, Suy ER.
PMID: 27397675
Acta Chir Belg. 2003 Jan;103(5):433. doi: 10.1080/00015458.2003.11681163.

No abstract available.

Cite
Nevelsteen A, Suy ER. In Memoriam Professor Dr. Hendrik Lacroix. Acta Chir Belg. 2003;103(5):433doi: 10.1080/00015458.2003.11681163.
Nevelsteen, A., & Suy, E. R. (2003). In Memoriam Professor Dr. Hendrik Lacroix. Acta chirurgica Belgica, 103(5), 433. https://doi.org/10.1080/00015458.2003.11681163
Nevelsteen, André, and Suy, Em Raphaël. "In Memoriam Professor Dr. Hendrik Lacroix." Acta chirurgica Belgica vol. 103,5 (2003): 433. doi: https://doi.org/10.1080/00015458.2003.11681163
Nevelsteen A, Suy ER. In Memoriam Professor Dr. Hendrik Lacroix. Acta Chir Belg. 2003 Jan;103(5):433. doi: 10.1080/00015458.2003.11681163. PMID: 27397675.
Copy Download .nbib Format: NLM
Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Slembrouck L, Vanden Bempt I, Wildiers H, Smeets A, Van Rompuy AS, Van Ongeval C, Jongen L, Weltens C, Punie K, Hoste G, Van Nieuwenhuysen E, Han S, Nevelsteen I, Neven P, Floris G.
PMID: 33558657
Mod Pathol. 2021 Jul;34(7):1297-1309. doi: 10.1038/s41379-021-00743-8. Epub 2021 Feb 08.

Multigene signatures (MGS) are used to guide adjuvant chemotherapy (aCT) decisions in patients diagnosed with estrogen receptor (ER)-positive HER2-negative early breast cancer. We used results from three MGS (Oncotype DX® (ODX), MammaPrint® (MP) or Prosigna®) and assessed the concordance...

Cite
Slembrouck L, Vanden Bempt I, Wildiers H, et al. Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer. Mod Pathol. 2021;34(7):1297-1309doi: 10.1038/s41379-021-00743-8.
Slembrouck, L., Vanden Bempt, I., Wildiers, H., Smeets, A., Van Rompuy, A. S., Van Ongeval, C., Jongen, L., Weltens, C., Punie, K., Hoste, G., Van Nieuwenhuysen, E., Han, S., Nevelsteen, I., Neven, P., & Floris, G. (2021). Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 34(7), 1297-1309. https://doi.org/10.1038/s41379-021-00743-8
Slembrouck, Laurence, et al. "Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 34,7 (2021): 1297-1309. doi: https://doi.org/10.1038/s41379-021-00743-8
Slembrouck L, Vanden Bempt I, Wildiers H, Smeets A, Van Rompuy AS, Van Ongeval C, Jongen L, Weltens C, Punie K, Hoste G, Van Nieuwenhuysen E, Han S, Nevelsteen I, Neven P, Floris G. Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer. Mod Pathol. 2021 Jul;34(7):1297-1309. doi: 10.1038/s41379-021-00743-8. Epub 2021 Feb 08. PMID: 33558657.
Copy Download .nbib Format: NLM
Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates.

Archives of public health = Archives belges de sante publique

Izci H, Tambuyzer T, Vandeven J, Xicluna J, Wildiers H, Punie K, Willers N, Oldenburger E, Van Nieuwenhuysen E, Berteloot P, Smeets A, Nevelsteen I, Deblander A, De Schutter H, Neven P, Silversmit G, Verdoodt F.
PMID: 34162431
Arch Public Health. 2021 Jun 23;79(1):111. doi: 10.1186/s13690-021-00637-w.

BACKGROUND: Registration and coding of cause of death is prone to error since determining the exact underlying condition leading directly to death is challenging. In this study, causes of death from the death certificates were compared to patients' medical...

Cite
Izci H, Tambuyzer T, Vandeven J, et al. Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates. Arch Public Health. 2021;79(1):111doi: 10.1186/s13690-021-00637-w.
Izci, H., Tambuyzer, T., Vandeven, J., Xicluna, J., Wildiers, H., Punie, K., Willers, N., Oldenburger, E., Van Nieuwenhuysen, E., Berteloot, P., Smeets, A., Nevelsteen, I., Deblander, A., De Schutter, H., Neven, P., Silversmit, G., & Verdoodt, F. (2021). Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates. Archives of public health = Archives belges de sante publique, 79(1), 111. https://doi.org/10.1186/s13690-021-00637-w
Izci, Hava, et al. "Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates." Archives of public health = Archives belges de sante publique vol. 79,1 (2021): 111. doi: https://doi.org/10.1186/s13690-021-00637-w
Izci H, Tambuyzer T, Vandeven J, Xicluna J, Wildiers H, Punie K, Willers N, Oldenburger E, Van Nieuwenhuysen E, Berteloot P, Smeets A, Nevelsteen I, Deblander A, De Schutter H, Neven P, Silversmit G, Verdoodt F. Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates. Arch Public Health. 2021 Jun 23;79(1):111. doi: 10.1186/s13690-021-00637-w. PMID: 34162431; PMCID: PMC8220845.
Copy Download .nbib Format: NLM
Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in .

Journal of oncology

Dullens B, de Putter R, Lambertini M, Toss A, Han S, Van Nieuwenhuysen E, Van Gorp T, Vanderstichele A, Van Ongeval C, Keupers M, Prevos R, Celis V, Dekervel J, Everaerts W, Wildiers H, Nevelsteen I, Neven P, Timmerman D, Smeets A, Denayer E, Van Buggenhout G, Legius E, Punie K.
PMID: 32655641
J Oncol. 2020 Jun 20;2020:9873954. doi: 10.1155/2020/9873954. eCollection 2020.

Germline pathogenic alterations in the breast cancer susceptibility genes 1 (

Cite
Dullens B, de Putter R, Lambertini M, et al. Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in . J Oncol. 2020;2020:9873954doi: 10.1155/2020/9873954.
Dullens, B., de Putter, R., Lambertini, M., Toss, A., Han, S., Van Nieuwenhuysen, E., Van Gorp, T., Vanderstichele, A., Van Ongeval, C., Keupers, M., Prevos, R., Celis, V., Dekervel, J., Everaerts, W., Wildiers, H., Nevelsteen, I., Neven, P., Timmerman, D., Smeets, A., Denayer, E., Van Buggenhout, G., Legius, E., & Punie, K. (2020). Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in . Journal of oncology, 20209873954. https://doi.org/10.1155/2020/9873954
Dullens, Boudewijn, et al. "Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in ." Journal of oncology vol. 2020 (2020): 9873954. doi: https://doi.org/10.1155/2020/9873954
Dullens B, de Putter R, Lambertini M, Toss A, Han S, Van Nieuwenhuysen E, Van Gorp T, Vanderstichele A, Van Ongeval C, Keupers M, Prevos R, Celis V, Dekervel J, Everaerts W, Wildiers H, Nevelsteen I, Neven P, Timmerman D, Smeets A, Denayer E, Van Buggenhout G, Legius E, Punie K. Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in . J Oncol. 2020 Jun 20;2020:9873954. doi: 10.1155/2020/9873954. eCollection 2020. PMID: 32655641; PMCID: PMC7322604.
Copy Download .nbib Format: NLM
Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer.

NPJ breast cancer

Vos H, Lambein K, Richard F, Mariën B, Nevelsteen I, Punie K, Wildiers H, Berben L, Laenen A, Floris G, Desmedt C, Smeets A.
PMID: 34556657
NPJ Breast Cancer. 2021 Sep 23;7(1):128. doi: 10.1038/s41523-021-00332-7.

The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast...

Cite
Vos H, Lambein K, Richard F, et al. Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer. NPJ Breast Cancer. 2021;7(1):128doi: 10.1038/s41523-021-00332-7.
Vos, H., Lambein, K., Richard, F., Mariën, B., Nevelsteen, I., Punie, K., Wildiers, H., Berben, L., Laenen, A., Floris, G., Desmedt, C., & Smeets, A. (2021). Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer. NPJ breast cancer, 7(1), 128. https://doi.org/10.1038/s41523-021-00332-7
Vos, Hanne, et al. "Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer." NPJ breast cancer vol. 7,1 (2021): 128. doi: https://doi.org/10.1038/s41523-021-00332-7
Vos H, Lambein K, Richard F, Mariën B, Nevelsteen I, Punie K, Wildiers H, Berben L, Laenen A, Floris G, Desmedt C, Smeets A. Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer. NPJ Breast Cancer. 2021 Sep 23;7(1):128. doi: 10.1038/s41523-021-00332-7. PMID: 34556657; PMCID: PMC8460670.
Copy Download .nbib Format: NLM
Correction to: Behavior of metastatic breast cancer according to subtype.

Breast cancer research and treatment

Van Mechelen M, Van Herck A, Punie K, Nevelsteen I, Smeets A, Neven P, Weltens C, Han S, Vanderstichele A, Floris G, Lobelle JP, Wildiers H.
PMID: 33410978
Breast Cancer Res Treat. 2021 Apr;186(2):587-589. doi: 10.1007/s10549-020-06006-5.

No abstract available.

Cite
Van Mechelen M, Van Herck A, Punie K, et al. Correction to: Behavior of metastatic breast cancer according to subtype. Breast Cancer Res Treat. 2021;186(2):587-589doi: 10.1007/s10549-020-06006-5.
Van Mechelen, M., Van Herck, A., Punie, K., Nevelsteen, I., Smeets, A., Neven, P., Weltens, C., Han, S., Vanderstichele, A., Floris, G., Lobelle, J. P., & Wildiers, H. (2021). Correction to: Behavior of metastatic breast cancer according to subtype. Breast cancer research and treatment, 186(2), 587-589. https://doi.org/10.1007/s10549-020-06006-5
Van Mechelen, Margot, et al. "Correction to: Behavior of metastatic breast cancer according to subtype." Breast cancer research and treatment vol. 186,2 (2021): 587-589. doi: https://doi.org/10.1007/s10549-020-06006-5
Van Mechelen M, Van Herck A, Punie K, Nevelsteen I, Smeets A, Neven P, Weltens C, Han S, Vanderstichele A, Floris G, Lobelle JP, Wildiers H. Correction to: Behavior of metastatic breast cancer according to subtype. Breast Cancer Res Treat. 2021 Apr;186(2):587-589. doi: 10.1007/s10549-020-06006-5. PMID: 33410978.
Copy Download .nbib Format: NLM
Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.

Translational oncology

Slembrouck L, Darrigues L, Laurent C, Mittempergher L, Delahaye LJ, Vanden Bempt I, Vander Borght S, Vliegen L, Sintubin P, Raynal V, Bohec M, Reyes C, Rapinat A, Helsmoortel C, Jongen L, Hoste G, Neven P, Wildiers H, Smeets A, Nevelsteen I, Punie K, Van Nieuwenhuysen E, Han S, Vincent Salomon A, Laas Faron E, Cynober T, Gentien D, Baulande S, Snel MH, Witteveen AT, Neijenhuis S, Glas AM, Reyal F, Floris G.
PMID: 31513983
Transl Oncol. 2019 Dec;12(12):1557-1565. doi: 10.1016/j.tranon.2019.08.008. Epub 2019 Sep 09.

A previously developed and centrally validated MammaPrint® (MP) and BluePrint® (BP) targeted RNA next-generation sequencing (NGS) kit was implemented and validated in two large academic European hospitals. Additionally, breast cancer molecular subtypes by MP and BP RNA sequencing were...

Cite
Slembrouck L, Darrigues L, Laurent C, et al. Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris. Transl Oncol. 2019;12(12):1557-1565doi: 10.1016/j.tranon.2019.08.008.
Slembrouck, L., Darrigues, L., Laurent, C., Mittempergher, L., Delahaye, L. J., Vanden Bempt, I., Vander Borght, S., Vliegen, L., Sintubin, P., Raynal, V., Bohec, M., Reyes, C., Rapinat, A., Helsmoortel, C., Jongen, L., Hoste, G., Neven, P., Wildiers, H., Smeets, A., Nevelsteen, I., Punie, K., Van Nieuwenhuysen, E., Han, S., Vincent Salomon, A., Laas Faron, E., Cynober, T., Gentien, D., Baulande, S., Snel, M. H., Witteveen, A. T., Neijenhuis, S., Glas, A. M., Reyal, F., & Floris, G. (2019). Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris. Translational oncology, 12(12), 1557-1565. https://doi.org/10.1016/j.tranon.2019.08.008
Slembrouck, Laurence, et al. "Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris." Translational oncology vol. 12,12 (2019): 1557-1565. doi: https://doi.org/10.1016/j.tranon.2019.08.008
Slembrouck L, Darrigues L, Laurent C, Mittempergher L, Delahaye LJ, Vanden Bempt I, Vander Borght S, Vliegen L, Sintubin P, Raynal V, Bohec M, Reyes C, Rapinat A, Helsmoortel C, Jongen L, Hoste G, Neven P, Wildiers H, Smeets A, Nevelsteen I, Punie K, Van Nieuwenhuysen E, Han S, Vincent Salomon A, Laas Faron E, Cynober T, Gentien D, Baulande S, Snel MH, Witteveen AT, Neijenhuis S, Glas AM, Reyal F, Floris G. Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris. Transl Oncol. 2019 Dec;12(12):1557-1565. doi: 10.1016/j.tranon.2019.08.008. Epub 2019 Sep 09. PMID: 31513983; PMCID: PMC6742807.
Copy Download .nbib Format: NLM
Personal and technological skills to coach people with noncommunicable diseases: development and validation of a scale for nursing students.

Heliyon

Parreira P, Santos-Costa P, Graveto J, Ferreira PA, Salgueiro-Oliveira A, Sousa LB, Bernardes RA, Serambeque B, Mónico L, Kapun MM, Gogova T, Vesa P, Vandenhoudt H, Nevelsteen D, Kokko R.
PMID: 33644450
Heliyon. 2021 Feb 02;7(2):e06140. doi: 10.1016/j.heliyon.2021.e06140. eCollection 2021 Feb.

BACKGROUND: Current international policies converge to the need of empowering patients and families in becoming more autonomous in the self-caring and management of their noncommunicable diseases (NCDs). Given their professional scope, nurses are the most well-positioned health professionals to...

Cite
Parreira P, Santos-Costa P, Graveto J, et al. Personal and technological skills to coach people with noncommunicable diseases: development and validation of a scale for nursing students. Heliyon. 2021;7(2):e06140doi: 10.1016/j.heliyon.2021.e06140.
Parreira, P., Santos-Costa, P., Graveto, J., Ferreira, P. A., Salgueiro-Oliveira, A., Sousa, L. B., Bernardes, R. A., Serambeque, B., Mónico, L., Kapun, M. M., Gogova, T., Vesa, P., Vandenhoudt, H., Nevelsteen, D., & Kokko, R. (2021). Personal and technological skills to coach people with noncommunicable diseases: development and validation of a scale for nursing students. Heliyon, 7(2), e06140. https://doi.org/10.1016/j.heliyon.2021.e06140
Parreira, Pedro, et al. "Personal and technological skills to coach people with noncommunicable diseases: development and validation of a scale for nursing students." Heliyon vol. 7,2 (2021): e06140. doi: https://doi.org/10.1016/j.heliyon.2021.e06140
Parreira P, Santos-Costa P, Graveto J, Ferreira PA, Salgueiro-Oliveira A, Sousa LB, Bernardes RA, Serambeque B, Mónico L, Kapun MM, Gogova T, Vesa P, Vandenhoudt H, Nevelsteen D, Kokko R. Personal and technological skills to coach people with noncommunicable diseases: development and validation of a scale for nursing students. Heliyon. 2021 Feb 02;7(2):e06140. doi: 10.1016/j.heliyon.2021.e06140. eCollection 2021 Feb. PMID: 33644450; PMCID: PMC7889991.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries